Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Solid Organ Transplant Recipients Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

NCT04349436
View directory record Official record
Conditions
Merkel Cell Carcinoma, Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Cancer
Interventions
RP1, intra-tumoral injection, oncolytic virus
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jun 10, 2026, 2:08 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

NCT03665675
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Cytomegalovirus, Donor, Solid Organ Transplantation Recipient, Adenovirus
Interventions
Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes, Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Biological
Lead sponsor
Sumithira Vasu
Other
Eligibility
1 Year to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 10, 2026, 2:08 AM EDT
Terminated Phase 2 Interventional Results available

Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

NCT04807777
View directory record Official record
Conditions
Advanced Cutaneous Squamous Cell Carcinoma
Interventions
Ruxolitinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jun 10, 2026, 2:08 AM EDT
Not yet recruiting Phase 4 Interventional

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

NCT07426484
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Skin Cancer
Interventions
Cosibelimab, Prednisone, Sirolimus, Everolimus
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 10, 2026, 2:08 AM EDT
Enrolling by invitation Phase 4 Interventional

CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients

NCT07009548
View directory record Official record
Conditions
Cytomegalovirus (CMV) Infection
Interventions
Cytogam
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Jun 10, 2026, 2:08 AM EDT
Terminated No phase listed Observational

Solid Organ Transplant SHINGRIX

NCT03993717
View directory record Official record
Conditions
Kidney Transplant; Complications
Interventions
SHINGRIX
Biological
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jun 10, 2026, 2:08 AM EDT
Completed No phase listed Observational

Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients

NCT02602262
View directory record Official record
Conditions
HIV Infection
Interventions
HIV-infected deceased donor organ
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
18
States / cities
Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Jun 10, 2026, 2:08 AM EDT
Completed No phase listed Observational

T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays

NCT02382211
View directory record Official record
Conditions
Infection in Solid Organ Transplant Recipients
Interventions
Not listed
Lead sponsor
Oxford Immunotec
Industry
Eligibility
18 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Tucson, Arizona • Irvine, California • Loma Linda, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Jun 10, 2026, 2:08 AM EDT
Completed Not applicable Interventional

Development of Discharge Education Video for Solid Organ Transplant Recipients

NCT05189340
View directory record Official record
Conditions
Educational Activities, Organ Transplants
Interventions
Educational Videos
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Jun 10, 2026, 2:08 AM EDT
Recruiting Phase 2 Interventional

Study Evaluating the Efficacy and Safety of Artesunate

NCT06853184
View directory record Official record
Conditions
CMV Infection
Interventions
Artesunate, Ganciclovir (GCV)
Drug
Lead sponsor
Amivas Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 10, 2026, 2:08 AM EDT
Terminated Phase 2 Interventional Results available

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

NCT03617445
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
FMT oral capsule, Oral Vancomycin, FMT oral placebo, Oral Vancomycin placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Jun 10, 2026, 2:08 AM EDT
Completed Not applicable Interventional Results available

A Study of mDOT for Immunosuppressant Adherence in Solid Organ Transplant Recipients

NCT04587024
View directory record Official record
Conditions
Medication Adherence, Liver Transplantation, Kidney Transplantation
Interventions
mHealth intervention, standard of care
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jun 10, 2026, 2:08 AM EDT
Terminated Phase 3 Interventional Results available

COVID-19 3rd Dose Vaccine in Transplant Patients

NCT05047640
View directory record Official record
Conditions
Covid19
Interventions
BNT162b2 vaccine, JNJ-78436735 Vaccine
Biological
Lead sponsor
Giselle Guerra
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Jun 10, 2026, 2:08 AM EDT
Recruiting No phase listed Observational

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

NCT05550298
View directory record Official record
Conditions
Hematopoietic Cell Transplant, Solid Organ Transplant, Respiratory Viral Infection
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 18 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jun 10, 2026, 2:08 AM EDT
Completed Not applicable Interventional

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

NCT05663463
View directory record Official record
Conditions
Solid Organ Transplant
Interventions
Fluzone High-Dose - 2 doses, Fluzone High-Dose - 1 dose of HD
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Jun 10, 2026, 2:08 AM EDT
Terminated Phase 1 Interventional

A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients

NCT03950414
View directory record Official record
Conditions
Cytomegalovirus Infections, Solid Organ Transplant
Interventions
CMV specific T-cells
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Jun 10, 2026, 2:08 AM EDT
Active, not recruiting Phase 4 Interventional

Immunogenicity of HPV Vaccine in Transplant Recipients.

NCT05557370
View directory record Official record
Conditions
Chronic Kidney Diseases, Kidney Transplant
Interventions
Human Papilloma Virus vaccine (GARDASIL 9)
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 10, 2026, 2:08 AM EDT
Recruiting Phase 2 Interventional

A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant

NCT07092865
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Adjuvanted RSVPreF3 vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Lexington, Kentucky • St Louis, Missouri • Omaha, Nebraska + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jun 10, 2026, 2:08 AM EDT
Completed No phase listed Observational

Parents of Pediatric Solid Organ Transplant Recipients: Transition to Home and Chronic Illness Care

NCT01389804
View directory record Official record
Conditions
Transplant
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
Chicago, Illinois • St Louis, Missouri • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2012 · Synced Jun 10, 2026, 2:08 AM EDT
Not listed No phase listed Observational

Virus Surveillance in Pediatric Solid Organ Transplant Recipients

NCT00886158
View directory record Official record
Conditions
Viral Infections
Interventions
Not listed
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Jun 10, 2026, 2:08 AM EDT
Completed No phase listed Observational

Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients

NCT01558037
View directory record Official record
Conditions
Awaiting Organ Transplant, Infection in Solid Organ Transplant Recipients
Interventions
Not listed
Lead sponsor
Michael Ison
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Jun 10, 2026, 2:08 AM EDT
Recruiting No phase listed Observational

Biomarkers in Transplant Recipients to Improve Outcomes

NCT01163578
View directory record Official record
Conditions
Solid Organ Transplantation, Bone Marrow Transplantation
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
Not listed
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Jun 10, 2026, 2:08 AM EDT
Completed No phase listed Observational

Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients

NCT05164016
View directory record Official record
Conditions
Cancer, Hematopoietic System--Cancer, Transplant-Related Cancer, Solid Tumor Malignancy, Hematologic Malignancy, Solid Organ Transplant, Hematopoietic Cell Transplant, Cellular Therapy
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 10, 2026, 2:08 AM EDT
Completed Phase 2 Interventional Results available

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

NCT02900976
View directory record Official record
Conditions
EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder, Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder, Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder
Interventions
Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab
Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jun 10, 2026, 2:08 AM EDT